Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.58 Billion KRW | -187.66% |
| 2022 | 12.07 Billion KRW | -55.53% |
| 2021 | 27.15 Billion KRW | -53.09% |
| 2020 | 57.89 Billion KRW | 839.77% |
| 2019 | -7.82 Billion KRW | 11.25% |
| 2018 | -8.81 Billion KRW | 11.3% |
| 2017 | -9.94 Billion KRW | 31.05% |
| 2016 | -14.41 Billion KRW | -168.4% |
| 2015 | -5.37 Billion KRW | 60.38% |
| 2014 | -13.55 Billion KRW | -89.57% |
| 2013 | -7.15 Billion KRW | 10.84% |
| 2012 | -8.02 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.85 Billion KRW | -348.93% |
| 2024 Q3 | -9.11 Billion KRW | -391.06% |
| 2024 Q1 | 746 Million KRW | 105.82% |
| 2023 Q4 | -12.81 Billion KRW | -2793.31% |
| 2023 Q1 | -467.33 Million KRW | 92.12% |
| 2023 Q3 | 475.94 Million KRW | -78.59% |
| 2023 FY | -10.58 Billion KRW | -187.66% |
| 2023 Q2 | 2.22 Billion KRW | 575.7% |
| 2022 Q3 | 8.64 Billion KRW | 1202.85% |
| 2022 Q2 | 663.92 Million KRW | -92.36% |
| 2022 FY | 12.07 Billion KRW | -55.53% |
| 2022 Q1 | 8.69 Billion KRW | 67.57% |
| 2022 Q4 | -5.92 Billion KRW | -168.55% |
| 2021 Q3 | -9.73 Billion KRW | -158.85% |
| 2021 Q2 | 16.54 Billion KRW | 9.11% |
| 2021 Q4 | 5.18 Billion KRW | 153.27% |
| 2021 FY | 27.15 Billion KRW | -53.09% |
| 2021 Q1 | 15.16 Billion KRW | -56.57% |
| 2020 Q2 | 41.28 Billion KRW | 297.07% |
| 2020 Q3 | 2.64 Billion KRW | -93.59% |
| 2020 Q4 | 34.91 Billion KRW | 1218.99% |
| 2020 Q1 | -20.94 Billion KRW | -604.37% |
| 2020 FY | 57.89 Billion KRW | 839.77% |
| 2019 Q1 | -2.71 Billion KRW | -23.39% |
| 2019 FY | -7.82 Billion KRW | 11.25% |
| 2019 Q4 | -2.97 Billion KRW | -110.3% |
| 2019 Q2 | -725.7 Million KRW | 73.25% |
| 2019 Q3 | -1.41 Billion KRW | -94.87% |
| 2018 Q4 | -2.19 Billion KRW | 13.37% |
| 2018 Q2 | -703.88 Million KRW | 79.16% |
| 2018 Q1 | -3.37 Billion KRW | 27.26% |
| 2018 FY | -8.81 Billion KRW | 11.3% |
| 2018 Q3 | -2.53 Billion KRW | -260.56% |
| 2017 Q1 | -2.53 Billion KRW | 3.05% |
| 2017 FY | -9.94 Billion KRW | 31.05% |
| 2017 Q4 | -4.64 Billion KRW | -217.93% |
| 2017 Q2 | -1.3 Billion KRW | 48.4% |
| 2017 Q3 | -1.46 Billion KRW | -11.86% |
| 2016 FY | -14.41 Billion KRW | -168.4% |
| 2016 Q1 | -2.85 Billion KRW | -110.36% |
| 2016 Q2 | -3.97 Billion KRW | -39.58% |
| 2016 Q4 | -2.61 Billion KRW | 56.05% |
| 2016 Q3 | -5.93 Billion KRW | -49.3% |
| 2015 Q4 | -1.35 Billion KRW | -648.0% |
| 2015 Q2 | -1.19 Billion KRW | 54.91% |
| 2015 Q1 | -2.64 Billion KRW | -6.76% |
| 2015 FY | -5.37 Billion KRW | 60.38% |
| 2015 Q3 | -181.13 Million KRW | 84.81% |
| 2014 Q3 | -4.34 Billion KRW | 5.38% |
| 2014 Q1 | -2.14 Billion KRW | 32.38% |
| 2014 FY | -13.55 Billion KRW | -89.57% |
| 2014 Q4 | -2.47 Billion KRW | 43.04% |
| 2014 Q2 | -4.59 Billion KRW | -114.67% |
| 2013 Q2 | -484.28 Million KRW | -104.08% |
| 2013 Q4 | -3.16 Billion KRW | 3.07% |
| 2013 Q3 | -3.26 Billion KRW | -574.32% |
| 2013 Q1 | -237.3 Million KRW | 77.01% |
| 2013 FY | -7.15 Billion KRW | 10.84% |
| 2012 FY | -8.02 Billion KRW | 0.0% |
| 2012 Q4 | -1.03 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 94.401% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -9.196% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 326.667% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -272.671% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 281.285% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 78.36% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 83.481% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -25.569% |
| Medy-Tox Inc. | 9.75 Billion KRW | 208.528% |
| Peptron, Inc. | -15.92 Billion KRW | 33.506% |
| Amicogen, Inc. | -23.28 Billion KRW | 54.54% |
| Genexine, Inc. | -66.87 Billion KRW | 84.169% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -359.874% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 85.636% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -213.991% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 113.83% |
| SillaJen, Inc. | -20.36 Billion KRW | 48.024% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 175.806% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 44.575% |
| Genomictree Inc. | -8.75 Billion KRW | -20.911% |
| MedPacto, Inc. | -35.32 Billion KRW | 70.029% |
| D&D Pharmatech | 3.93 Billion KRW | 369.13% |
| EASY BIO,Inc. | 15.54 Billion KRW | 168.111% |
| GI Innovation, Inc. | -55.49 Billion KRW | 80.923% |